29. Other Liabilities

Other liabilities comprised:

Other Liabilities

 

 

Dec. 31, 2014

 

Dec. 31, 2015

 

 

Total

Of which current

 

Total

Of which current

 

 

€ million

€ million

 

€ million

€ million

Other tax liabilities

 

477

433

 

435

428

Deferred income

 

1,136

207

 

1,148

204

Liabilities to employees

 

196

185

 

217

210

Liabilities for social expenses

 

154

140

 

174

165

Accrued interest on liabilities

 

201

192

 

189

180

Miscellaneous liabilities

 

713

632

 

436

347

Total

 

2,877

1,789

 

2,599

1,534

Deferred income included an upfront payment, originally amounting to US$1 billion, in connection with the strategic pharmaceutical collaboration agreed between Bayer and Merck & Co., Inc., United States, in the field of soluble guanylate cyclase (sGC) modulation. The deferred income is being amortized over a period of 13.5 years as the obligations are satisfied. The remaining amount deferred at the end of 2015 was €719 million (2014: €778 million). The amount amortized in 2015 was €59 million (2014: €15 million).

The deferred income included €62 million (2014: €70 million) in grants and subsidies received from governments, of which €7 million (2014: €8 million) was reversed and recognized in profit or loss.

The miscellaneous liabilities included €125 million (2014: €204 million) from derivatives.